CervoMed Net Worth
CervoMed Net Worth Breakdown | CRVO |
CervoMed Net Worth Analysis
CervoMed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including CervoMed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of CervoMed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform CervoMed's net worth analysis. One common approach is to calculate CervoMed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares CervoMed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing CervoMed's net worth. This approach calculates the present value of CervoMed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of CervoMed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate CervoMed's net worth. This involves comparing CervoMed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into CervoMed's net worth relative to its peers.
Enterprise Value |
|
To determine if CervoMed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding CervoMed's net worth research are outlined below:
| CervoMed had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 9.74 M. Net Loss for the year was (16.29 M) with loss before overhead, payroll, taxes, and interest of (11.51 M). | |
| CervoMed generates negative cash flow from operations | |
| CervoMed has a poor financial position based on the latest SEC disclosures | |
| About 33.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3 |
CervoMed Quarterly Good Will |
|
CervoMed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in CervoMed. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to CervoMed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow CervoMed's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 64.49 M.Market Cap |
|
Project CervoMed's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.46) | (0.49) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.42) | (0.44) |
When accessing CervoMed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures CervoMed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of CervoMed's profitability and make more informed investment decisions.
Evaluate CervoMed's management efficiency
CervoMed has return on total asset (ROA) of (0.5619) % which means that it has lost $0.5619 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9342) %, meaning that it created substantial loss on money invested by shareholders. CervoMed's management efficiency ratios could be used to measure how well CervoMed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of July 2025, Return On Tangible Assets is likely to drop to -0.4. In addition to that, Return On Capital Employed is likely to drop to -0.49. At this time, CervoMed's Asset Turnover is very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.86 | 5.10 | |
| Tangible Book Value Per Share | 4.86 | 5.10 | |
| Enterprise Value Over EBITDA | (0.54) | (0.57) | |
| Price Book Value Ratio | 0.48 | 0.46 | |
| Enterprise Value Multiple | (0.54) | (0.57) | |
| Price Fair Value | 0.48 | 0.46 | |
| Enterprise Value | 9.9 M | 9.4 M |
The leadership approach at CervoMed's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CervoMed insiders, such as employees or executives, is commonly permitted as long as it does not rely on CervoMed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases CervoMed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
CervoMed Corporate Filings
F4 | 25th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 23rd of May 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 19th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
CervoMed Earnings per Share Projection vs Actual
CervoMed Corporate Management
| Dr Cobuzzi | Chief Officer | Profile | |
| Mark Rosch | Government Regulatory | Profile | |
| Claudia MD | Senior Science | Profile | |
| John Tanner | Chief Officer | Profile | |
| Marinus Verwijs | Executive Operations | Profile | |
| William JD | General Secretary | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CervoMed. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in CervoMed Stock, please use our How to Invest in CervoMed guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CervoMed. If investors know CervoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CervoMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.17) | Revenue Per Share | Quarterly Revenue Growth (0.18) | Return On Assets | Return On Equity |
The market value of CervoMed is measured differently than its book value, which is the value of CervoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CervoMed's value that differs from its market value or its book value, called intrinsic value, which is CervoMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CervoMed's market value can be influenced by many factors that don't directly affect CervoMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CervoMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if CervoMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CervoMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.